{"id":26735,"date":"2024-01-19T15:12:26","date_gmt":"2024-01-19T20:12:26","guid":{"rendered":"https:\/\/myeloma.ca\/?p=26735"},"modified":"2024-01-19T15:14:07","modified_gmt":"2024-01-19T20:14:07","slug":"lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/","title":{"rendered":"L\u2019ann\u00e9e 2023 s\u2019est termin\u00e9e sur une bonne note avec l\u2019approbation d\u2019elranatamab par Sant\u00e9 Canada!\u00a0"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">My\u00e9lome Canada est fier d\u2019annoncer que le 11 d\u00e9cembre dernier, Sant\u00e9 Canada a publi\u00e9 un<a href=\"https:\/\/health-products.canada.ca\/noc-ac\/nocInfo?no=32309&amp;lang=fre\" target=\"_blank\" rel=\"noreferrer noopener\"> avis de conformit\u00e9 avec conditions <\/a>(AC avec conditions) pour elranatamab (Elrexfio).\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Elrexfio (elranatamab en solution sous-cutan\u00e9e) est indiqu\u00e9 pour le traitement des adultes atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire qui ont re\u00e7u au moins 3 traitements ant\u00e9rieurs, dont un inhibiteur du prot\u00e9asome, un agent immunomodulateur et un anticorps monoclonal anti-CD38.\u00a0<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Cliquez ici pour consulter les <a href=\"https:\/\/health-products.canada.ca\/dpd-bdpp\/info?code=103201&amp;lang=fre\" target=\"_blank\" rel=\"noreferrer noopener\">renseignements sur le produit (canada.ca)<\/a>&nbsp;<\/p>\n","protected":false},"excerpt":{"rendered":"<p>My\u00e9lome Canada est fier d\u2019annoncer que le 11 d\u00e9cembre dernier, Sant\u00e9 Canada a publi\u00e9 un avis de conformit\u00e9 avec conditions (AC avec conditions) pour elranatamab (Elrexfio).\u00a0 Elrexfio (elranatamab en solution sous-cutan\u00e9e) est indiqu\u00e9 pour le traitement des adultes atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire qui ont re\u00e7u au moins 3 traitements ant\u00e9rieurs, dont un [&hellip;]<\/p>\n","protected":false},"author":10,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":"","_members_access_role":[],"_members_access_error":""},"categories":[88,53],"tags":[],"class_list":["post-26735","post","type-post","status-publish","format-standard","hentry","category-actualites","category-actualites-et-evenement"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t<!-- All in One SEO 5.0.0.1 - aioseo.com -->\n\t<meta name=\"description\" content=\"My\u00e9lome Canada est fier d\u2019annoncer que le 11 d\u00e9cembre dernier, Sant\u00e9 Canada a publi\u00e9 un avis de conformit\u00e9 avec conditions (AC avec conditions) pour elranatamab (Elrexfio). Elrexfio (elranatamab en solution sous-cutan\u00e9e) est indiqu\u00e9 pour le traitement des adultes atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire qui ont re\u00e7u au moins 3 traitements ant\u00e9rieurs, dont un\" \/>\n\t<meta name=\"robots\" content=\"max-image-preview:large\" \/>\n\t<meta name=\"author\" content=\"Leigh Kinch-Pedrosa\"\/>\n\t<link rel=\"canonical\" href=\"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/\" \/>\n\t<meta name=\"generator\" content=\"All in One SEO (AIOSEO) 5.0.0.1\" \/>\n\t\t<meta property=\"og:locale\" content=\"fr_FR\" \/>\n\t\t<meta property=\"og:site_name\" content=\"My\u00e9lome Canada |\" \/>\n\t\t<meta property=\"og:type\" content=\"article\" \/>\n\t\t<meta property=\"og:title\" content=\"L\u2019ann\u00e9e 2023 s\u2019est termin\u00e9e sur une bonne note avec l\u2019approbation d\u2019elranatamab par Sant\u00e9 Canada! | My\u00e9lome Canada\" \/>\n\t\t<meta property=\"og:description\" content=\"My\u00e9lome Canada est fier d\u2019annoncer que le 11 d\u00e9cembre dernier, Sant\u00e9 Canada a publi\u00e9 un avis de conformit\u00e9 avec conditions (AC avec conditions) pour elranatamab (Elrexfio). Elrexfio (elranatamab en solution sous-cutan\u00e9e) est indiqu\u00e9 pour le traitement des adultes atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire qui ont re\u00e7u au moins 3 traitements ant\u00e9rieurs, dont un\" \/>\n\t\t<meta property=\"og:url\" content=\"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/\" \/>\n\t\t<meta property=\"article:published_time\" content=\"2024-01-19T20:12:26+00:00\" \/>\n\t\t<meta property=\"article:modified_time\" content=\"2024-01-19T20:14:07+00:00\" \/>\n\t\t<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n\t\t<meta name=\"twitter:title\" content=\"L\u2019ann\u00e9e 2023 s\u2019est termin\u00e9e sur une bonne note avec l\u2019approbation d\u2019elranatamab par Sant\u00e9 Canada! | My\u00e9lome Canada\" \/>\n\t\t<meta name=\"twitter:description\" content=\"My\u00e9lome Canada est fier d\u2019annoncer que le 11 d\u00e9cembre dernier, Sant\u00e9 Canada a publi\u00e9 un avis de conformit\u00e9 avec conditions (AC avec conditions) pour elranatamab (Elrexfio). Elrexfio (elranatamab en solution sous-cutan\u00e9e) est indiqu\u00e9 pour le traitement des adultes atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire qui ont re\u00e7u au moins 3 traitements ant\u00e9rieurs, dont un\" \/>\n\t\t<script type=\"application\/ld+json\" class=\"aioseo-schema\">\n\t\t\t{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"BlogPosting\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/01\\\/19\\\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\\\/#blogposting\",\"name\":\"L\\u2019ann\\u00e9e 2023 s\\u2019est termin\\u00e9e sur une bonne note avec l\\u2019approbation d\\u2019elranatamab par Sant\\u00e9 Canada! | My\\u00e9lome Canada\",\"headline\":\"L\\u2019ann\\u00e9e 2023 s\\u2019est termin\\u00e9e sur une bonne note avec l\\u2019approbation d\\u2019elranatamab par Sant\\u00e9 Canada!\\u00a0\",\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/#author\"},\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"},\"image\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#articleImage\"},\"datePublished\":\"2024-01-19T15:12:26-05:00\",\"dateModified\":\"2024-01-19T15:14:07-05:00\",\"inLanguage\":\"fr-FR\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/01\\\/19\\\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\\\/#webpage\"},\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/01\\\/19\\\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\\\/#webpage\"},\"articleSection\":\"Actualit\\u00e9s, Actualit\\u00e9s et \\u00e9v\\u00e9nement\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/01\\\/19\\\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\\\/#breadcrumblist\",\"itemListElement\":[{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"position\":2,\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites\\\/#listItem\",\"name\":\"Actualit\\u00e9s\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#listItem\",\"name\":\"Accueil\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites\\\/#listItem\",\"position\":3,\"name\":\"Actualit\\u00e9s\",\"item\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites\\\/\",\"nextItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/01\\\/19\\\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\\\/#listItem\",\"name\":\"L\\u2019ann\\u00e9e 2023 s\\u2019est termin\\u00e9e sur une bonne note avec l\\u2019approbation d\\u2019elranatamab par Sant\\u00e9 Canada!\\u00a0\"},\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/#listItem\",\"name\":\"Actualit\\u00e9s et \\u00e9v\\u00e9nement\"}},{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/01\\\/19\\\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\\\/#listItem\",\"position\":4,\"name\":\"L\\u2019ann\\u00e9e 2023 s\\u2019est termin\\u00e9e sur une bonne note avec l\\u2019approbation d\\u2019elranatamab par Sant\\u00e9 Canada!\\u00a0\",\"previousItem\":{\"@type\":\"ListItem\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/category\\\/actualites-et-evenement\\\/actualites\\\/#listItem\",\"name\":\"Actualit\\u00e9s\"}}]},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\",\"name\":\"Myeloma Canada\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"telephone\":\"+18887985771\",\"logo\":{\"@type\":\"ImageObject\",\"url\":\"https:\\\/\\\/stage.myeloma.ca\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/logo_en.png\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/01\\\/19\\\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\\\/#organizationLogo\"},\"image\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/01\\\/19\\\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\\\/#organizationLogo\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/#author\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/\",\"name\":\"Leigh Kinch-Pedrosa\",\"image\":{\"@type\":\"ImageObject\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/01\\\/19\\\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\\\/#authorImage\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/bc9a857bcf898667f0e3d913441f25e1d2d9d652d14911323fd2e018121c78a3?s=96&d=mm&r=g\",\"width\":96,\"height\":96,\"caption\":\"Leigh Kinch-Pedrosa\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/01\\\/19\\\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\\\/#webpage\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/01\\\/19\\\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\\\/\",\"name\":\"L\\u2019ann\\u00e9e 2023 s\\u2019est termin\\u00e9e sur une bonne note avec l\\u2019approbation d\\u2019elranatamab par Sant\\u00e9 Canada! | My\\u00e9lome Canada\",\"description\":\"My\\u00e9lome Canada est fier d\\u2019annoncer que le 11 d\\u00e9cembre dernier, Sant\\u00e9 Canada a publi\\u00e9 un avis de conformit\\u00e9 avec conditions (AC avec conditions) pour elranatamab (Elrexfio). Elrexfio (elranatamab en solution sous-cutan\\u00e9e) est indiqu\\u00e9 pour le traitement des adultes atteints d\\u2019un my\\u00e9lome multiple r\\u00e9cidivant ou r\\u00e9fractaire qui ont re\\u00e7u au moins 3 traitements ant\\u00e9rieurs, dont un\",\"inLanguage\":\"fr-FR\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/2024\\\/01\\\/19\\\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\\\/#breadcrumblist\"},\"author\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/#author\"},\"creator\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/author\\\/leigh-kp\\\/#author\"},\"datePublished\":\"2024-01-19T15:12:26-05:00\",\"dateModified\":\"2024-01-19T15:14:07-05:00\"},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/\",\"name\":\"Myeloma Canada\",\"inLanguage\":\"fr-FR\",\"publisher\":{\"@id\":\"https:\\\/\\\/myeloma.ca\\\/fr\\\/#organization\"}}]}\n\t\t<\/script>\n\t\t<!-- All in One SEO -->\n\n","aioseo_head_json":{"title":"L\u2019ann\u00e9e 2023 s\u2019est termin\u00e9e sur une bonne note avec l\u2019approbation d\u2019elranatamab par Sant\u00e9 Canada! | My\u00e9lome Canada","description":"My\u00e9lome Canada est fier d\u2019annoncer que le 11 d\u00e9cembre dernier, Sant\u00e9 Canada a publi\u00e9 un avis de conformit\u00e9 avec conditions (AC avec conditions) pour elranatamab (Elrexfio). Elrexfio (elranatamab en solution sous-cutan\u00e9e) est indiqu\u00e9 pour le traitement des adultes atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire qui ont re\u00e7u au moins 3 traitements ant\u00e9rieurs, dont un","canonical_url":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/","robots":"max-image-preview:large","keywords":"","webmasterTools":{"miscellaneous":""},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"BlogPosting","@id":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/#blogposting","name":"L\u2019ann\u00e9e 2023 s\u2019est termin\u00e9e sur une bonne note avec l\u2019approbation d\u2019elranatamab par Sant\u00e9 Canada! | My\u00e9lome Canada","headline":"L\u2019ann\u00e9e 2023 s\u2019est termin\u00e9e sur une bonne note avec l\u2019approbation d\u2019elranatamab par Sant\u00e9 Canada!\u00a0","author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/#author"},"publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"},"image":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/#articleImage"},"datePublished":"2024-01-19T15:12:26-05:00","dateModified":"2024-01-19T15:14:07-05:00","inLanguage":"fr-FR","mainEntityOfPage":{"@id":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/#webpage"},"isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/#webpage"},"articleSection":"Actualit\u00e9s, Actualit\u00e9s et \u00e9v\u00e9nement"},{"@type":"BreadcrumbList","@id":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","position":1,"name":"Accueil","item":"https:\/\/myeloma.ca\/fr\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","position":2,"name":"Actualit\u00e9s et \u00e9v\u00e9nement","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites\/#listItem","name":"Actualit\u00e9s"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/#listItem","name":"Accueil"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites\/#listItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites\/","nextItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/#listItem","name":"L\u2019ann\u00e9e 2023 s\u2019est termin\u00e9e sur une bonne note avec l\u2019approbation d\u2019elranatamab par Sant\u00e9 Canada!\u00a0"},"previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/#listItem","name":"Actualit\u00e9s et \u00e9v\u00e9nement"}},{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/#listItem","position":4,"name":"L\u2019ann\u00e9e 2023 s\u2019est termin\u00e9e sur une bonne note avec l\u2019approbation d\u2019elranatamab par Sant\u00e9 Canada!\u00a0","previousItem":{"@type":"ListItem","@id":"https:\/\/myeloma.ca\/fr\/category\/actualites-et-evenement\/actualites\/#listItem","name":"Actualit\u00e9s"}}]},{"@type":"Organization","@id":"https:\/\/myeloma.ca\/fr\/#organization","name":"Myeloma Canada","url":"https:\/\/myeloma.ca\/fr\/","telephone":"+18887985771","logo":{"@type":"ImageObject","url":"https:\/\/stage.myeloma.ca\/wp-content\/uploads\/2023\/02\/logo_en.png","@id":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/#organizationLogo"},"image":{"@id":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/#organizationLogo"}},{"@type":"Person","@id":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/#author","url":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/","name":"Leigh Kinch-Pedrosa","image":{"@type":"ImageObject","@id":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/bc9a857bcf898667f0e3d913441f25e1d2d9d652d14911323fd2e018121c78a3?s=96&d=mm&r=g","width":96,"height":96,"caption":"Leigh Kinch-Pedrosa"}},{"@type":"WebPage","@id":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/#webpage","url":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/","name":"L\u2019ann\u00e9e 2023 s\u2019est termin\u00e9e sur une bonne note avec l\u2019approbation d\u2019elranatamab par Sant\u00e9 Canada! | My\u00e9lome Canada","description":"My\u00e9lome Canada est fier d\u2019annoncer que le 11 d\u00e9cembre dernier, Sant\u00e9 Canada a publi\u00e9 un avis de conformit\u00e9 avec conditions (AC avec conditions) pour elranatamab (Elrexfio). Elrexfio (elranatamab en solution sous-cutan\u00e9e) est indiqu\u00e9 pour le traitement des adultes atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire qui ont re\u00e7u au moins 3 traitements ant\u00e9rieurs, dont un","inLanguage":"fr-FR","isPartOf":{"@id":"https:\/\/myeloma.ca\/fr\/#website"},"breadcrumb":{"@id":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/#breadcrumblist"},"author":{"@id":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/#author"},"creator":{"@id":"https:\/\/myeloma.ca\/fr\/author\/leigh-kp\/#author"},"datePublished":"2024-01-19T15:12:26-05:00","dateModified":"2024-01-19T15:14:07-05:00"},{"@type":"WebSite","@id":"https:\/\/myeloma.ca\/fr\/#website","url":"https:\/\/myeloma.ca\/fr\/","name":"Myeloma Canada","inLanguage":"fr-FR","publisher":{"@id":"https:\/\/myeloma.ca\/fr\/#organization"}}]},"og:locale":"fr_FR","og:site_name":"My\u00e9lome Canada |","og:type":"article","og:title":"L\u2019ann\u00e9e 2023 s\u2019est termin\u00e9e sur une bonne note avec l\u2019approbation d\u2019elranatamab par Sant\u00e9 Canada! | My\u00e9lome Canada","og:description":"My\u00e9lome Canada est fier d\u2019annoncer que le 11 d\u00e9cembre dernier, Sant\u00e9 Canada a publi\u00e9 un avis de conformit\u00e9 avec conditions (AC avec conditions) pour elranatamab (Elrexfio). Elrexfio (elranatamab en solution sous-cutan\u00e9e) est indiqu\u00e9 pour le traitement des adultes atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire qui ont re\u00e7u au moins 3 traitements ant\u00e9rieurs, dont un","og:url":"https:\/\/myeloma.ca\/fr\/2024\/01\/19\/lannee-2023-sest-terminee-sur-une-bonne-note-avec-lapprobation-delranatamab-par-sante-canada\/","article:published_time":"2024-01-19T20:12:26+00:00","article:modified_time":"2024-01-19T20:14:07+00:00","twitter:card":"summary_large_image","twitter:title":"L\u2019ann\u00e9e 2023 s\u2019est termin\u00e9e sur une bonne note avec l\u2019approbation d\u2019elranatamab par Sant\u00e9 Canada! | My\u00e9lome Canada","twitter:description":"My\u00e9lome Canada est fier d\u2019annoncer que le 11 d\u00e9cembre dernier, Sant\u00e9 Canada a publi\u00e9 un avis de conformit\u00e9 avec conditions (AC avec conditions) pour elranatamab (Elrexfio). Elrexfio (elranatamab en solution sous-cutan\u00e9e) est indiqu\u00e9 pour le traitement des adultes atteints d\u2019un my\u00e9lome multiple r\u00e9cidivant ou r\u00e9fractaire qui ont re\u00e7u au moins 3 traitements ant\u00e9rieurs, dont un"},"aioseo_meta_data":{"post_id":"26735","title":null,"description":null,"keywords":[],"keyphrases":{"focus":{"keyphrase":"","score":0,"analysis":{"keyphraseInTitle":{"score":0,"maxScore":9,"error":1}}},"additional":[]},"primary_term":null,"canonical_url":null,"og_title":null,"og_description":null,"og_object_type":"default","og_image_type":"default","og_image_url":null,"og_image_width":null,"og_image_height":null,"og_image_custom_url":null,"og_image_custom_fields":null,"og_video":"","og_custom_url":null,"og_article_section":null,"og_article_tags":[],"twitter_use_og":false,"twitter_card":"default","twitter_image_type":"default","twitter_image_url":null,"twitter_image_custom_url":null,"twitter_image_custom_fields":null,"twitter_title":null,"twitter_description":null,"schema":{"blockGraphs":[],"customGraphs":[],"default":{"data":{"Article":[],"Course":[],"Dataset":[],"FAQPage":[],"Movie":[],"Person":[],"Product":[],"ProductReview":[],"Car":[],"Recipe":[],"Service":[],"SoftwareApplication":[],"WebPage":[]},"graphName":"BlogPosting","isEnabled":true},"graphs":[]},"schema_type":"default","schema_type_options":null,"pillar_content":false,"robots_default":true,"robots_noindex":false,"robots_noarchive":false,"robots_nosnippet":false,"robots_nofollow":false,"robots_noimageindex":false,"robots_noodp":false,"robots_notranslate":false,"robots_max_snippet":"-1","robots_max_videopreview":"-1","robots_max_imagepreview":"large","priority":null,"frequency":"default","local_seo":null,"breadcrumb_settings":null,"limit_modified_date":false,"ai":null,"created":"2024-01-19 20:14:08","updated":"2026-04-30 08:43:04","seo_analyzer_scan_date":null,"focus_keyword":null,"additional_keywords":null,"truseo_locale":null},"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/26735","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=26735"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/26735\/revisions"}],"predecessor-version":[{"id":26737,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/26735\/revisions\/26737"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=26735"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=26735"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=26735"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}